$4.89
-0.04 (-0.81%)
Open$4.92
Previous Close$4.93
Day High$5.13
Day Low$4.86
52W High$13.50
52W Low$2.28
Volume—
Avg Volume94.8K
Market Cap63.49M
P/E Ratio—
EPS$-2.57
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+285.7% upside
Current
$4.89
$4.89
Target
$18.86
$18.86
$15.04
$18.86 avg
$28.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 242.0K | 321.7K | 28.89M |
| Net Income | -31,650,736 | -37,869,798 | 2.55M |
| Profit Margin | -13,086.5% | -12,432.2% | 8.8% |
| EBITDA | -28,237,445 | -35,662,819 | 4.88M |
| Free Cash Flow | — | — | 2.44M |
| Rev Growth | -24.8% | -24.8% | +0.1% |
| Debt/Equity | 1.99 | 1.99 | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |